ARV-6723
Solid Malignancies
Phase 1Active
Key Facts
About Arvinas
Arvinas is a leader in the field of targeted protein degradation, founded on groundbreaking research from Yale University. The company's PROTAC® platform enables the development of therapeutics that harness the body's natural protein disposal system to degrade disease-causing proteins, potentially addressing previously 'undruggable' targets. With multiple clinical-stage assets, strategic partnerships, and a robust discovery engine, Arvinas aims to revolutionize treatment for serious diseases in oncology and neurology.
View full company profile